Friday , May 15, 2015 08:20ET
NEW YORK, May 15, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ladder Capital Corp (NYSE: LADR), New York REIT, Inc. (NYSE: NYRT), The J.G. Wentworth Company (NYSE: JGW), Pain Therapeutics Inc. (NASDAQ: PTIE), and MYOS Corporation (NASDAQ: MYOS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
LADR Research Report: ( http://get.analystsreview.com/pdf/?c=Ladder%20Capital&d=15-May-2015&s=LADR ),
NYRT Research Report: ( http://get.analystsreview.com/pdf/?c=New%20York%20REIT&d=15-May-2015&s=NYRT ),
JGW Research Report: ( http://get.analystsreview.com/pdf/?c=J.G.%20Wentworth&d=15-May-2015&s=JGW ),
PTIE Research Report: ( http://get.analystsreview.com/pdf/?c=Pain%20Therapeutics&d=15-May-2015&s=PTIE ),
MYOS Research Report: ( http://get.analystsreview.com/pdf/?c=MYOS%20Corp.&d=15-May-2015&s=MYOS ).
============
--
Analyst Update: Financial and Operational Results and Clinical Trials
U.S. stocks closed higher on Thursday, recovering from a sequence of slight losses over the week. The rally came despite unexpected drop in both weekly jobless claims and headline inflation figure. The NASDAQ Composite closed at 5,050.79, up 1.39%, the S&P 500 jumped 1.08%, to 2,121.10, and the Dow Jones Industrial Average ended the session 1.06% higher, at 18,252.24. European stocks surged sharply higher on Thursday after the European Central Bank's president reaffirmed its commitment to continue massive stimulus program for the Eurozone. Germany's DAX 30 advanced 1.84%, France's CAC 40 gained 1.36%, and London's FTSE 100 closed 0.34% higher on Thursday. Meanwhile, Asian markets were once again mixed on Thursday. The Shanghai Composite and Hong Kong's Hang Seng posted modest gains, while Japan's Nikkei fell on Thursday.
On May 6, 2015, Ladder Capital Corp. announced its financial and operational results for the first quarter of 2015. The Company reported a net income of $18 million for the quarter. The Company's Core Earnings, which is a non-GAAP measure, was $48 million for Q1 2015. On a per share basis, the net earnings worked out to $0.18 whereas Core EPS, a non-GAAP measure, was $0.48 for Q1 2015.
New York REIT, Inc. (NYR) announced its financial and operating results for the first quarter of 2015 on May 11, 2015. The Company recorded Same Store Cash Net Operating Income for the first quarter 2015 of $26.8 million versus $23.9 million in Q1 2014, a year-on-year increase of 12%. The Company's portfolio occupancy was 95.2% as of March 31, 2015, compared to 94.9% sequentially.
The J.G. Wentworth Company announced its financial and operational results for the first quarter of 2015 on May 11, 2015. The Company reported an increase in its total receivables balance purchases to $260.8 million for Q1 2015 versus $260.6 million in Q1 2014. The Company announced its intention to enter mortgage category with the acquisition of WestStar Mortgage, Inc. on March 6, 2015.
On May 12, 2015, Pain Therapeutics, Inc. announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.
On May 11, 2015, MYOS Corp. announced the initiation of a dose response clinical study of Fortetropin(R) in modestly resistance trained subjects. The study will be led by, Jacob Wilson, Ph.D, CSCS*D, Professor of Health Sciences and Human Performance at the University of Tampa, and will examine the effects of Fortetropin(R) supplementation on plasma myostatin levels at various dosing levels.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Recent SAVA News
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 09/24/2024 12:30:00 PM
- Cassava Sciences Names Rick Barry as Chief Executive Officer • GlobeNewswire Inc. • 09/09/2024 12:30:00 PM
- Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:31:00 PM
- Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson • GlobeNewswire Inc. • 08/05/2024 01:01:00 PM
- Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET • GlobeNewswire Inc. • 08/01/2024 12:30:00 PM
- Cassava Sciences Announces Expansion of Open-Label Extension Trials • GlobeNewswire Inc. • 07/30/2024 12:15:00 PM
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Cassava Sciences Issues Statement on Former Science Advisor • GlobeNewswire Inc. • 06/28/2024 07:58:09 PM
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam • GlobeNewswire Inc. • 05/10/2024 08:02:00 PM
- Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution • GlobeNewswire Inc. • 05/08/2024 03:00:00 PM
- Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ • GlobeNewswire Inc. • 05/01/2024 01:10:00 PM
- Redemption Date Announced for Warrants • GlobeNewswire Inc. • 04/15/2024 01:20:00 PM
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 03/25/2024 01:13:00 PM
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference • GlobeNewswire Inc. • 03/04/2024 02:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:01:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:22:12 PM
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates • GlobeNewswire Inc. • 02/28/2024 02:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 02:20:27 PM
- No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months • GlobeNewswire Inc. • 02/07/2024 02:08:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:00:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:45 PM
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders • GlobeNewswire Inc. • 01/05/2024 02:12:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 01/03/2024 09:24:43 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 01/03/2024 09:22:52 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM